Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (13999)	7/5/2000 7:07:27 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Robert, did or did not the phase II subjects get blood? Of course they did. So they got their share of the bpi the same as did P III. Please explain to me why blood only became so beneficial in P II. If you do not explain quickly, I will sick, el perro latino, on you.

To: Robert K. who wrote (13999)	7/6/2000 6:11:09 PM
From: Cacaito	Respond to of 17367

Rk, I did express high concern BEFORE the pIII was stop, I actually presented all the pII results, several weeks before the DSMB stopped the trial, and I clearly predicted that " the only good thing will be if the DSMB says: continue, no safety problem" WAY CLEARLY before the actual event. My bad move was that I wrongly bet that it was going to take many more months for DSMB decision. No time to bring the actual post, I get it later. I also said that the same way that IPIC took Takeda for a ride, xoma TOOK the Bax for a ride! at almost the same cost of close to $10M, and it was also true! xoma indeed took the bax for a ride!!! Both were before the event!!! I do not believe xoma, neither the bax!